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Abstract
Purpose Whereas anti-oestrogen therapy is widely applied to
treat oestrogen receptor (ER) positive breast cancer, paradox-
ically, oestrogens can also induce tumour regression. Up-
regulation of ER expression is a marker for oestrogen hyper-
sensitivity. We, therefore, performed an exploratory study to
evaluate positron emission tomography (PET) with the tracer
16α-[18F]fluoro-17β-oestradiol (18F-FES) as potential marker
to select breast cancer patients for oestradiol therapy.
Methods Eligible patients had acquired endocrine-resistant
metastatic breast cancer that progressed after ≥2 lines of en-
docrine therapy. All patients had prior ER-positive histology.
Treatment consisted of oestradiol 2 mg, three times daily,
orally. Patients underwent 18F-FES-PET/CT imaging at base-
line. Tumour 18F-FES-uptake was quantified for a maximum
of 20 lesions and expressed as maximum standardised uptake
value (SUVmax). CT-scan was repeated every 3 months to
evaluate treatment response. Clinical benefit was defined as
time to radiologic or clinical progression ≥24 weeks.
Results 18F-FES uptake, quantified for 255 lesions in 19 pa-
tients, varied greatly between lesions (median 2.8; range 0.6–
24.3) and between patients (median 2.5; range 1.1–15.5). Sev-
en (37 %) patients experienced clinical benefit of oestrogen
therapy, eight progressed (PD), and four were non-evaluable
due to side effects. The positive and negative predictive value
(PPV/NPV) of 18F-FES-PET for response to treatment were
60 % (95 % CI: 31–83 %) and 80 % (95 % CI: 38–96 %),
respectively, using SUVmax >1.5.
Conclusion 18F-FES-PET may aid identification of patients
with acquired antihormone resistant breast cancer that are un-
likely to benefit from oestradiol therapy.
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Introduction
Until the introduction of tamoxifen, additive oestrogens such
as the synthetic diethylstilbestrol (DES) were considered the
hormone treatment of choice in postmenopausal women. In a
randomised study in 143 postmenopausal patients with meta-
static breast cancer, first-line endocrine therapy with DES was
equally effective as tamoxifen with a response rate of 41% vs.
33 %. Yet, tamoxifen became the preferred agent because it
showed fewer side effects [1]. An emerging number of anti-
oestrogen therapies have become available since. Recently,
however, additive oestrogen therapy has regained interest by
showing efficacy in ~35 % of patients that are extensively pre-
treated with anti-oestrogens [2]. Interestingly, an update of the
randomised study showed a superior 5-year survival for DES
compared to tamoxifen (35 % vs. 16 %) after 14 years of
follow-up [3]. Moreover, in a recent study a lower dose of
only 6 mg oestradiol rendered similar clinical benefit rates as
30 mg oestradiol with fewer side effects. Finally, clinical re-
sults suggest that oestrogens can restore the sensitivity to anti-
oestrogens [4]. As the majority of patients will not benefit
from additive oestrogen therapy, a biomarker for patient se-
lection would be helpful.
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In preclinical studies, long-term oestrogen deprivation trig-
gered hypersensitivity to oestrogens, which is accompanied
by a five- to 10-fold increase in ER expression [5, 6]. Thus,
patients that have been treated with anti-oestrogens for a long
time may likewise have become hypersensitive to oestrogens.
If so, patients that are most likely to benefit from oestradiol
therapy could potentially be identified by high tumour ER
expression. Positron emission tomography (PET) with
16α-[18F]fluoro-17β-oestradiol (18F-FES) can visualise and
quantify ER expression in breast cancer lesions [7]. The aim
of this exploratory study was, therefore, to evaluate 18F-FES-
PET as a potential marker to select breast cancer patients for
oestradiol therapy.
In the setting of ER-positive metastatic breast cancer, re-
sponse assessment is notoriously difficult due to the high in-
cidence of bone metastases. Bone is the most common site
affected in breast cancer [8]. However, bone metastases are
regarded non-measurable by the response evaluation criteria
in solid tumours (RECIST) [9]. This underlines the need for
objective measures to predict and evaluate response, for ex-
ample by molecular imaging techniques. Recent studies have
shown that 18F-FES-PET can predict response to various
forms of anti-oestrogen therapy [10–13]. Its value as a bio-
marker for additive oestrogen therapy is, however, unknown.
In addition to molecular imaging techniques, also serum
markers may be valuable to assess response in patients with
bone-dominant disease in which response assessment is diffi-
cult. The ASCO recommendations for the use of tumour
markers in breast cancer indicate that CA 15.3 and CEA can
be considered to monitor treatment effects [14]. Also, bone
turnover markers such as procollagen type I amino-terminal
propeptide (PINP), carboxyl-terminal telopeptide of type I
collagen (CTx), and bone alkaline phosphatase (BALP) are
reported to correlate with the number and size of bone metas-
tases in breast and prostate cancer [15–17]. Therefore, in ad-
dition to 18F-FES-PET, we also evaluated whether tumour




The trial was conducted in accordance with the principles of
Good Clinical Practice and the Declaration of Helsinki. The
protocol was approved by the local medical ethics committee
and registered in the ClinicalTrials.gov database
(NCT01088477). All patients provided written informed
consent.
Eligible patients had acquired endocrine-resistant advanced
breast cancer showing progression after ≥2 lines of endocrine
t h e r apy. A l l p a t i e n t s h ad e a r l i e r ER-po s i t i v e
immunohistochemical tumour staining, and were required to
have responded to at least one prior line of anti-hormone ther-
apy (objective response or stable disease ≥6 months). Other
eligibility criteria were ECOG performance ≤2 and life expec-
tancy ≥3 months. Exclusion criteria were the presence of
symptomatic central nervous system lesions, a history of
thrombosis, diabetes mellitus, uncontrolled hypercalcaemia,
treatment with investigational drugs within 30 days before
the start of study, dyspnoea at rest due to any cause, and class
III or IV congestive heart failure according to the New York
Heart Association. Patients were required to withdraw drugs
known to bind ER for at least 5 weeks prior to baseline imag-
ing [18].
Oestradiol treatment
Patients were treated with oestradiol three times daily 2 mg
orally [4]. Therapy was initiated within 4 days after 18F-FES-
PET/CT. In case of toxicity oestradiol dosing was reduced to
twice daily 2 mg, or shortly interrupted with re-introduction at
a lower dose when the symptoms had resolved. Therapy was
continued until progressive disease (PD) by radiologic or clin-
ical assessment, withdrawal of consent, or severe toxicity.
Toxicity was documented according to the Common Termi-
nology Criteria of Adverse Events v3.0.
Assessment of treatment response
Baseline measurements included documentation of all symp-
toms, performance status, physical examination, laboratory
tests (including blood counts, kidney function, and liver en-
zymes), and a diagnostic CT-scan. Clinical follow-up with
documentation of symptoms, performance status, physical ex-
amination, and laboratory tests were done monthly. A diag-
nostic CT-scan was performed every 3 months until progres-
sion. For patients with measurable disease, response was de-
fined according to RECIST v1.1 [9]. Patients with only non-
measurable lesions were considered to have PD when there
was unequivocal progression of existing lesions or when new
lesions were detected at follow-up. In the absence of radiolog-
ical PD, patients could develop clinical PD, defined as an
overall level of substantial worsening such that the overall
tumour burden or complaints increased sufficiently to merit
discontinuation of therapy [9]. In reference to other studies,
patients with time-to-progression ≥24 weeks were considered
to have obtained clinical benefit from oestradiol therapy [19].
Study measurements
18F-FES was produced and administered to the patient as de-
scribed earlier [18, 20]. On average 3.4±1.5 GBq 18F-FES
was obtained with 100 % radiochemical purity and a 325±
274 GBq/μmol specific activity. Patients received
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approximately 200 MBq 18F-FES intravenously. 18F-FES-
PET/CT to evaluate tumour ER-expression was performed at
baseline on a hybrid PET/CT camera with a 64-slice CT and
high definition and time-of-flight PET (Siemens Medical Sys-
tems). Low-dose CT-scan was used for attenuation correction
in all patients. Patients were scanned from skull to mid-thigh,
3 min per bed position (usually 7–8 bed positions per patient).
In all patients, baseline 18F-FES-PET was combined with a
contrast-enhanced diagnostic CT scan. For representative
18F-FES-PET, CT and 18F-FES-PET/CT images see Fig. 1.
Tumour 18F-FES uptake was quantified by a nuclear med-
icine physician according to the guidelines of the European
Association of Nuclear Medicine (EANM) for an arbitrary
maximum of 20 randomly chosen lesions per patient [21].
Whole-body CT-scan was evaluated by a radiologist and used
to allocate tumour lesions and identify possible 18F-FES-neg-
ative lesions. Lesion 18F-FES-uptake was expressed as maxi-
mum standardised uptake value (SUVmax). To calculate the
predictive value of 18F-FES-PET for treatment response in
individual patients, the median SUVmax of all lesions quanti-
fied was used. Quantification of tumour 18F-FES-uptake was
performed while blinded for treatment outcome. Patients and
treating physician were held blinded for 18F-FES-PET results.
Tumour markers (CA-15.3, CEA) and bone turnover
markers (PINP, CTx, and BALP) were also determined at
baseline and repeated every 3 months or at the time of pro-
gression. Patients were considered evaluable for tumour mark-
er response if one or both tumour markers were increased at
baseline (CA15.3>33 kU/L, CEA >5 μg/L). A 10 % increase
in tumour marker was defined as biochemical progression.
Patients were considered evaluable for bone turnover markers
when they had evidence of bone metastases on imaging. Se-
rum PINP >95 ng/mL was considered the threshold for in-
creased bone turnover based on literature [17]. For CTx and
BALP, the optimum thresholds were determined by receiver
operating characteristic (ROC) analysis.
Statistical analysis
The expected study time frame was 3 years for inclusion of 50
patients to evaluate the positive predictive value (PPV) and
negative predictive value (NPV) of 18F-FES-PET/CT for re-
sponse to oestradiol therapy by ROC analysis. After 3 years
and 21 patients included, the study was terminated. We here
report the PPVand NPV for 18F-FES-PET/CT, which was the
predefined primary end point of the study. PPVand NPVwere
calculated using a ROC analysis for the median tumour
SUVmax in patients. The association between biochemical tu-
mour markers and bone turnover markers and benefit from
oestradiol was calculated by a Mann–Whitney U test. Analy-
ses were performed in SPSS Statistics version 20.0.
Results
Patient characteristics
Between May 2010 and May 2013, 30 patients were screened
for participation in the trial, out of whom 21 were included
and 19 started oestradiol therapy, one man and 18 women.
Mean age was 57 years (range 36–76). Seventeen patients
had bone metastases; 14 patients also had visceral or nodal
metastases. Two patients had only visceral lesions. All pa-
tients had postmenopausal status, which was in two patients
achieved by the use of LHRH agonists, while others were
truly postmenopausal. Tumour histology was positive for
ER in all patients, 12 (63 %) were also PR positive, and none
were HER2 positive. All patients were heavily pre-treated; 11
patients had already received 3–4 lines of systemic therapy,
and seven patients ≥5 lines. Patient characteristics are
summarised in Table 1. For an overview of screening, inclu-




Fig. 1 18F-FES-PET (a), CT (b) and 18F-FES-PET/CT (c) of a patient
with bone metastases. Indicated is a rib metastasis (arrow) with SUVmax
3.3
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Tumour response
Twelve patients had measurable lesions on baseline CT ac-
cording to RECIST, four patients had non-measurable visceral
lesions, and three patients had only bone metastases. Four of
19 (21 %) discontinued oestradiol because of side effects and
were, therefore, not evaluable for treatment response.
Seven of the remaining 15 patients experienced clinical
benefit from oestradiol therapy as indicated by stable disease
≥24 weeks. Four had radiological measurable stable disease,
and three patients had no new lesions detected on radiological
examination, no progression of non-measurable lesions, im-
provement or stabilization of symptoms, and no evidence of
biochemical progression ≥24 weeks. They eventually experi-
enced PD according to RECIST criteria at 26, 28, and
48 weeks, respectively.
Finally, eight patients had PD; in five there was radiologic
PD and in three patients there was substantial clinical deteri-
oration, meriting discontinuation of therapy. One had labora-
tory signs of bone marrow invasion, confirmed with a biopsy;
one had rising liver function test values, a threefold increase in
tumour marker CA15.3, and clinical deterioration; and one
patient had deterioration of pain symptoms from bone lesions,
rising alkaline phosphatase, and worsening of performance
score. Overall clinical benefit rate was 37 % in all treated
patients (intention-to-treat; n=19 patients) and 47 % in all
patients available for response assessment (n=15 patients).
Mean progression-free-survival was 4.7 months (range 0.4–
15.3months). Oestradiol therapy induced an increase in serum
oestradiol levels from 89±15 pmol/L at baseline to 1241±225
pmol/L after 1 month of therapy. The increase in oestradiol
levels was equal among responders and non-responders.
Toxicity
In four patients (21 %), oestradiol therapy was terminat-
ed prematurely due to adverse events. These side effects
were progressive thrombocytopenia (n=1), transient is-
chemic accident with atrial fibrillation (n=1), mood dis-
orders (n=1), and signs of congestive heart failure (n=
1). Other grade 3 serious adverse events requiring hos-
p i t a l a dm i s s i o n w e r e t umo u r f l a r e ( n = 1 ) ,
hypercalcaemia (n=2), pneumonia (n=1), and atrial fi-
brillation (n=1). The patient who experienced a tumour
flare had rapid increase of pain symptoms at known
metastatic sites, starting as early as the day after initia-
tion of oestrogen therapy. Laboratory results were sug-
gestive of tumour flare with increased lactate dehydro-
genase and other liver enzymes. Symptoms and labora-
tory findings resolved after oestradiol discontinuation.
Interestingly, this patient with grade 3 clinical flare re-
action showed highest tumour uptake of 18F-FES (me-
dian SUVmax 15.5, maximum SUVmax 24.3). Common,
Table 1 Patient characteristics
Baseline characteristics All patients (n=19)
Male : female 1 : 18
Age, mean years (range) 57 (36–76)
Site of metastases, n









Progesterone receptor positive 12
HER2 positive 0
Prior systemic therapies, n
< 3 lines 1
3 or 4 lines 11





Included in the 
study
(n = 21)
•Excluded (n = 4)
- History of thromboembolic
events (n = 1) 
- Symptomatic CNS lesions
(n = 1)
- ECOG performance status
>2 (n = 2)
•Did not provide consent or




• Developed symptomatic brain
metastases prior to 18F-FES





• Brain metastases on 18F-FES
PET which appeared to be
symptomatic after neurological




Fig. 2 CONSORT diagram. CNS Central nervous system, ECOG
Eastern Cooperative Oncology Group
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but manageable grade 1–2 adverse events were tumour
flare, fatigue, nausea, and vaginal bleeding.
Predictive value of 18F-FES-PET for response
to oestradiol therapy
18F-FES uptake in tumour lesions was quantified for a total of
255 lesions (214 bone, 24 lung, 12 lymph nodes, one breast,
one soft-tissue, and one brain lesion) out of which 42 (16 %)
were 18F-FES-negative (SUVmax <1.5). Twelve out of 19 pa-
tients (63 %) had only 18F-FES-positive lesions, six (32 %)
had both FES-positive and FES-negative lesions, and one had
only FES-negative lesions. Absolute 18F-FES-uptake
(SUVmax) varied widely between lesions (median 2.8; range
0.6–24.3) and patients (median 2.5; range 1.1–15.5), as is
depicted in Fig. 3a and b. ROC analysis indicated that the
most optimum threshold to differentiate between patients with
clinical benefit and patients with PD was a median SUVmax of
>1.5. For patients with response assessment available (n=15
patients), this threshold produced a PPV of 60 % (95 % CI:
31–83 %) and an NPVof 80 % (95 % CI: 38–96 %) (Fig. 4a),
with an area under curve of 0.62.
Nine patients terminated treatment with ER-antagonists
5 weeks before initiating oestrogen therapy. Three of these
patients had an earlier 18F-FES-PET obtained in another
study (NCT01377324). These patients had much lower
18F-FES-uptake than on the earlier scans and several lesions
could no longer be observed. For example, one patient had,
on earlier 18F-FES-PET, a median tumour18F-FES-uptake of
6.5, while in the current study, SUVmax was only 1.1. This
patient benefited from oestradiol despite the relatively low
tumour 18F-FES-uptake. The remaining six patients had no
earlier scans available, but also had relatively low tumour
18F-FES-uptake compared to patients without recent use of
drugs that can bind ER. Thus, ER-antagonists may reduce
tumour 18F-FES-uptake beyond the currently used 5-week
drug withdrawal period [18]. In an explorative analysis,
using the results of the previous 18F-FES-PET scans instead
of the current PET scans, the PPV and NPV increased to 64
and 100 %, respectively (Fig. 4b).
Tumour markers and bone turnover markers
Seventeen patients had increased tumour markers. A tumour
marker response was seen in seven patients. The PPV and
NPV for tumour marker response were 67 and 71 %,
respectively.
Bone turnover markers were explored as potential effect
sensors in patients with bone metastases. Mean levels were
175 ng/mL for PINP (range 17–613 ng/mL), 90 U/L for
BALP (range 27–298 U/L), and 467 pg/mL for sCTx (range
26–1369 pg/mL). Change in bone turnover markers was not
associated with treatment response. Baseline PINP levels were
85 vs. 234 ng/mL (P=0.032), and sCTx levels 195 pg/mL vs.
623 pg/mL (P=0.032) in patients with clinical benefit and PD,
respectively. The PPVof baseline PINPwas 100% (five out of
five patients with PINP ≤95 ng/mL responded) and the NPV
88 % (seven out of eight patients with PINP >95 ng/mL
progressed) [17]. All four patients with sCTx levels
<200 pg/mL responded, and seven of nine patients with sCTX
>200 pg/mL progressed. BALP levels were non-informative
in this exploratory study. The PPV and NPV for 18F-
FES-PET/CT, tumour markers, and the bone turnover
































































Fig. 3 18F-FES-uptake (SUVmax) in bone lesions (a) and non-bone lesions (b) in all individual patients. The dashed line indicates the 1.5 (SUVmax)
threshold
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Discussion
This is the first exploratory study evaluating 18F-FES-PET/CT
as predictive marker for oestradiol therapy in patients with
metastatic endocrine resistant breast cancer. While the mech-
anism of anti-oestrogen therapy is well known, this is not the
case for the addition of oestrogens. Based on preclinical data,
we hypothesised that very high 18F-FES uptake would predict
response to oestradiol therapy. The value of 18F-FES-PET,
however, turned out to be especially its ability to identify
patients that are unlikely to benefit from oestradiol therapy
as a result of low or absent 18F-FES uptake in metastases.
There are currently no good upfront predictive biomarkers
to select patients for oestradiol therapy. Assessing ER status
by a biopsy is the current gold standard, but is sometimes
unreliable due to heterogeneous ER expression within and
among lesions, and detection of non-functional ER.
2′-[18F]fluoro-2′-deoxyglucose (18F-FDG) PET imaging has
been tested to predict response to oestradiol therapy. A study
randomised 66 patients to 6 or 30 mg oestradiol daily, 43
patients underwent 18F-FDG-PET imaging before and 24 h
after the initiation of oestrogen therapy [4]. A metabolic flare
reaction upon oestradiol therapy, predefined as a ≥12 % in-
crease in tumour 18F-FDG-uptake, had a PPVof 80 % (12 of
15 patients), and an NPVof 87% (27/31 patients) for response
to oestradiol therapy. Metabolic flare on 18F-FDG-PET in 51
patients subsequently treated with an aromatase inhibitor or
fulvestrant had an even higher PPVand NPVof 100 and 94 %
[12]. 18F-FES-PET was evaluated earlier in three studies as a
predictive biomarker before the initiation of aromatase inhib-
itors, tamoxifen, or fulvestrant. In these studies, the PPV of
18F-FES-PET ranged between 32 and 79 % and the NPV
between 82 and 100 % [10–12], which is comparable with
our findings. It is hypothesised that a negative 18F-FES-PET
can identify tumours that have lost ER-expression during the
course of disease [7, 10–12]. Recently, ESR1 (ER) gene mu-
tations have been described, some of which strongly reduce
ligand binding affinity and induce endocrine resistance [22].
These phenomena might explain the good NPVof low tumour
uptake of 18F-FES.
Our study has some limitations. First, the number of pa-
tients included was lower than expected. A possible explana-
tion is that, despite the fact that previous studies have shown
the safety and benefits of oestradiol therapy, physicians may
be reluctant to refer patients for oestrogen therapy given that
anti-oestrogen therapy is the key method to treat patients with
ER-positive disease. Secondly, given the low number of mea-




































































Fig. 4 a Association between 18F-FES-uptake and treatment outcome.
Patients with clinical benefit (CB), progressive disease (PD), and non-
evaluable (NE) patients are indicated. The dashed line indicates the 1.5
(SUVmax) threshold. Patients indicated in white had recently been treated
with ER-antagonists. b In three patients, indicated in gray, a previous 18F-
FES-PET scan was available. Using this scan resulted in an improvement
of the PPVand NPV
Table 2 Association between 18F-FES-PET, tumour markers, bone
marker, and treatment outcome
Marker Result n Response Predictive value
CB PD NE PPV NPV
18F-FES-PET SUV ≥1.5 10 6 4 (4) 60 %
SUV <1.5 5 1 4 (0) 80 %
Tumour marker R 6 4 2 (1) 67 %
NR 7 2 5 (3) 71 %
NE 2 1 1 (0)
Bone marker <95 pg/mL 5 5 0 (1) 100 %
PINP ≥95 pg/mL 8 1 7 (3) 88 %
NE 2 1 1 (0)
CB clinical benefit, PD progressive disease, NE non-evaluable, PPV pos-
itive predictive value, NPV negative predictive value, R response, NR
non-response
Eur J Nucl Med Mol Imaging (2015) 42:1674–1681 1679
to evaluate the correlation between 18F-FES uptake and re-
sponse in individual lesions. Also, we used CT to identify
18F-FES-negative lesions. It is possible that 18F-FDG-PET
together with 18F-FES-PET increases the sensitivity for 18F-
FES-negative lesions, since bone lesions are especially diffi-
cult to characterise on CT. Finally, when evaluating the pre-
dictive value of 18F-FES-PET, it is important to take concom-
itant and recent therapies into account. We observed low 18F-
FES-uptake in several previously 18F-FES-avid lesions in pa-
tients that had used ER-antagonists up to 5 weeks before 18F-
FES-PET. It is possible that the long half-lives (t½) of
fulvestrant (t½=40 days) and of tamoxifen and metabolites
(t½=9 and 13 days, respectively) are responsible for the 18F-
FES-negative results [23–25]. However, in the absence of
biopsies, we are unable to dissect fully whether the observed
effects can be attributed to altered ER-expression or to spill-
over effects of recent therapies.
In preclinical studies, long-term oestrogen-deprived ER-
positive breast cancer cells are used to study oestrogen-
induced apoptosis. After several months of culturing in
oestrogen-deprived conditions, breast cancer cells adapt to
the low levels of oestrogens by increasing ER expression
[26, 27]. Paradoxically, therapeutic doses of oestrogens now
no longer induce growth proliferation, but induce apoptosis.
More recently, ESR1 gene amplification was described in
patient-derived mouse xenografts as a possible marker for
hypersensitivity to oestradiol [28]. It would, therefore, be of
interest in future studies to combine 18F-FES-PET/CT with
analysis of ESR1 gene amplification and mutation in tumour
biopsies, in order potentially to improve the selection of pa-
tients for oestrogen therapy.
Although ER expression is required for response to endo-
crine agents, ER-positive tumours may still fail to respond,
e.g., due to cross talk with other pathways. We, therefore,
evaluated whether the addition of tumour and bone turnover
markers could improve response prediction. The association
of tumour marker response alone with the patient response
classification was modest and did not add significantly to
18F-FES-PET/CT. For bone turnover markers, not the changes
in bone markers during treatment, but the pre-treatment values
were associated with time-to-progression. These markers are
known to correlate with the number and size of bone metas-
tases in breast and prostate cancer [15–17]. Therefore, high
serum bone markers may be useful to identify patients that
have a poor prognosis independent of the therapy given.
Whether bone markers are of prognostic or predictive value
needs to be addressed in larger studies, adhering to REMARK
criteria [29].
We observed a clinical benefit rate of 37 % for oestradiol
6 mg orally daily, which is comparable to the study by Ellis
et al. [4]. Our study is the second evaluating this low-dose
regimen, as compared to the previous standard of 30mg orally
daily. The clinical benefit rate observed in our study in patients
that were extensively pre-treated (median of four prior regi-
mens) provides further evidence for the efficacy of oestradiol
6 mg daily. The 21 % of patients that terminated treatment
prematurely due to toxicity was relatively high; grade 3 ad-
verse events were noted in 42 % of the patients. The high
incidence of toxicity, however, underlines the value of upfront
predictive markers for this treatment.
Conclusion
Patients with acquired endocrine-resistant metastatic breast
cancer may paradoxically benefit from oestradiol therapy.
The relatively low response rate and toxicity accompanying
oestradiol therapy warrants exploration of potential bio-
markers to predict response. 18F-FES-PET/CT may aid to
identify patients that are unlikely to respond to oestradiol
therapy.
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